Skip to main content
Premium Trial:

Request an Annual Quote

Taconic to Sell Medicyte's Hepatocyte Cell Strains

NEW YORK (GenomeWeb News) – Taconic and Medicyte announced a sales and marketing agreement covering Medicyte's products.

Under the terms of the deal, Taconic will promote and sell Medicyte's human primary Upcyte hepatocyte cell strains and corresponding media, which have been developed for in vitro applications. According to the companies, the deal strengthens Taconic's tADMET portfolio of models, and expands Medicyte's distribution and market visibility, while at the same time providing entry into new markets for its hepatocyte cell strains.

The tADMET products are genetically and tissue humanized mouse cells and in vitro tools and services for improving the predictability of drug response in humans. Translational research applications for tADMET include studies in drug metabolism, toxicology and safety, and infectious diseases of the liver.

Financial and other terms of the deal were not disclosed.

"Human hepatocytes are indispensable for many applications in research, drug screening, and development," Joris Braspenning, managing director of Medicyte, said in a statement. "However, the availability of primary human hepatocytes is limited and their quality is variable. With the Upcyte hepatocytes, we can bring predictive, reliable, and standardized cells on the market to close the gap."

Medicyte, based in Heidelberg, Germany, develops controlled, scalable, and standardized human primary cell products. Taconic, located in New York's Hudson River Valley, provides genetically engineered mouse and rat models and services.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.